Buspirone: What is it all about?

  title={Buspirone: What is it all about?},
  author={Clare Loane and Marios Politis},
  journal={Brain Research},

Vilazodone for the Treatment of Depression: An Update

Vilazodone is a novel antidepressant having a selective serotonin (5-HT) reuptake inhibitor and 5-HT1A receptor partial agonist profile and 2 RCTs recently documented the efficacy and safety of vilazdone in patients with generalized anxiety disorder, which could be a start of broadening vilazodones usage or FDA approval in diverse anxiety disorders.

Therapeutic doses of buspirone block D3 receptors in the living primate brain.

For oral buspirone to achieve greater than 80% sustained D3R occupancy, as might be needed to treat addiction, higher doses than those used to treat anxiety (maximal 60 mg) will be required.

New-Onset Sleepwalking in a Patient Treated With Buspirone.

The effects of buspirone seem to be mediated via its strong partial agonist activity on the serotonin 5HT1a receptor, although it also has weak affinity for 5HT2 and α-1 adrenergic receptors and can act as a D2 receptor antagonist.

Safety and Tolerability of Anxiolytics/Sedative-Hypnotics

Emerging evidence indicates that pregabalin, a pharmacological agent approved for the treatment of generalized anxiety disorder, also has the potential to lead to abuse and dependence, and is still valuable in the management of anxiety disorders and transient insomnia.

Levo-Tetrahydroberberrubine Produces Anxiolytic-Like Effects in Mice through the 5-HT1A Receptor

The results suggest that l-THBr may produce potent anxiolytic-like effects mainly through serotonin receptors.

Expression of serotonin 1A and 2A receptors in molecular- and projection-defined neurons of the mouse insular cortex

A molecular and neuroanatomical map of the 5-HT system within the insular cortex is defined, providing ground knowledge to identify the potential role of serotonergic modulation of selective insular populations in anxiety.

Studies of the Effects of a Complex of Buspirone with Glycyrrhyzic Acid on the Behavior of Mice during Formation of an Anxious-Depressive State

The possible mechanisms of action of these compounds on the background of changes in the sensitivity of brain 5-HT1A receptors due to the formation of the pathological state in mice due to social stress are discussed.



Molecular basis of buspirone's anxiolytic action.

Even though buspirone and the benzodiazepines do not obviously share a common mode of action, the possibility is discussed that there is an underlying common mechanism of responsible for their antianxiety effects.

Buspirone, Parkinson's disease, and the locus ceruleus.

Clinical observations support the concept that central noradrenergic stimulation can adversely affect parkinsonian symptoms.

Attenuation of apomorphine-induced sensitization by buspirone

Dopamine receptor antagonism by the novel antianxiety drug, buspirone

The data suggest that buspirone enhances DA neuronal activity, in part, by weakly inhibiting presynaptic DA receptors, and that the drug has minimal effects on postsynapticDA receptors.

Pharmacology and neurochemistry of buspirone.

Buspirone appears to interact only with the dopaminergic system and possesses properties that are similar to both dopamine agonists and dopamine antagonists.

Neuropharmacology of buspirone.

Buspirone is a clinically effective anxiolytic with a unique structure and pharmacology which distinguishes it from the benzodiazepines. It has been termed anxioselective because it lacks

Hormonal response to buspirone is not impaired in major depression

The hypothesis of an altered postsynaptic 5‐HT1A receptor function in major depression is not supported and results indicate no consistent changes in the hormonal response to the 5‐ HT1A agonist buspirone in depressed patients.

Drug therapies for tardive dyskinesia: part 2.

  • R. Howland
  • Medicine, Biology
    Journal of psychosocial nursing and mental health services
  • 2011
Tardive dyskinesia (TD) is a serious complication associated with the long-term use of dopamine receptor-blocking drugs, and a number of drugs appear to have some benefit for its treatment.

[Effect of buspirone, a serotonergic 5-HT-1A agonist in cerebellar ataxia: a pilot study. Preliminary communication].

Preliminary data might confirm a link between cerebellar ataxia and the metabolism of serotonin, as suggested by the proposed serotonergic hypothesis.